keyword
MENU ▼
Read by QxMD icon Read
search

Bladder cancer

keyword
https://www.readbyqxmd.com/read/29165714/blood-lipid-genetic-scores-the-hmgcr-gene-and-cancer-risk-a-mendelian-randomization-study
#1
Marju Orho-Melander, George Hindy, Signe Borgquist, Christina-Alexandra Schulz, Jonas Manjer, Olle Melander, Tanja Stocks
Background: It is unclear whether there are causal associations between blood lipids, statin use and cancer risks. Under certain assumptions, Mendelian randomization analysis of a genetic marker for an exposure eliminates reverse causation and confounding. Methods: We applied Mendelian randomization analysis to genetic scores, comprising 26-41 single-nucleotide polymorphisms (SNPs), as instrumental variables (IVs) for triglycerides and low- and high-density lipoprotein cholesterol (LDLC, HDLC), using a prospective cohort of 26 904 individuals in which there were 6607 incident cancers...
November 20, 2017: International Journal of Epidemiology
https://www.readbyqxmd.com/read/29165379/role-of-non-coding-rnas-in-the-etiology-of-bladder-cancer
#2
REVIEW
Caterina Gulìa, Stefano Baldassarra, Fabrizio Signore, Giuliano Rigon, Valerio Pizzuti, Marco Gaffi, Vito Briganti, Alessandro Porrello, Roberto Piergentili
According to data of the International Agency for Research on Cancer and the World Health Organization (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organization Mortality), bladder is among the top ten body locations of cancer globally, with the highest incidence rates reported in Southern and Western Europe, North America, Northern Africa and Western Asia. Males (M) are more vulnerable to this disease than females (F), despite ample frequency variations in different countries, with a M:F ratio of 4...
November 22, 2017: Genes
https://www.readbyqxmd.com/read/29164059/intravesical-gemcitabine-versus-intravesical-bacillus-calmette-gu%C3%A3-rin-for-the-treatment-of-non-muscle-invasive-bladder-cancer-an-evaluation-of-efficacy-and-toxicity
#3
Thiru Prasanna, Paul Craft, Gayathri Balasingam, Hodo Haxhimolla, Ganes Pranavan
Background: Intravesical Bacillus Calmette-Guérin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common. Objectives: To compare the efficacy and toxicity of intravesical BCG and gemcitabine in the treatment of NMIBC. Methods: Retrospective data were collected in the region of Canberra, Australia from January 2010 to December 2015...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29163840/an-improved-nerve-sparing-radical-hysterectomy-technique-for-cervical-cancer-using-the-paravesico-vaginal-space-as-a-new-surgical-landmark
#4
Yuqin Zhang, Tingyan Shi, Sheng Yin, Sining Ma, Di Shi, Jun Guan, Libing Xiang, Yang Liu, Yulan Ren, Deyan Tan, Rongyu Zang
Bladder dysfunction remains a major postoperative challenge for early stage cervical cancer patients. The present prospective phase 2 trial in patients with stage IB1 and IIA1 cervical cancer follows up on our previous, unpublished work describing a new surgical landmark, the paravesico-vaginal space. We describe a novel nerve-sparing radical hysterectomy (NSRH) approach to treat early stage cervical cancer without compromising local control rate or survival. Between September 2015 and August 2016, 49 patients were enrolled to receive NSRH...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29163683/knockdown-of-hmgn5-increases-the-chemosensitivity-of-human-urothelial-bladder-cancer-cells-to-cisplatin-by-targeting-pi3k-akt-signaling
#5
Yu Gan, Leye He, Kun Yao, Jing Tan, Qing Zeng, Yingbo Dai, Jianye Liu, Yuxin Tang
High-mobility group nucleosome-binding domain 5 (HMGN5) is the latest member of the HMGN family of proteins. Numerous studies have confirmed the carcinogenic role of HMGN5 in cancer, but its function in the regulation of chemosensitivity is largely unknown and controversial. A previous study by the authors of the present study demonstrated that HMGN5 contributes to the progression of urothelial bladder cancer (UBC) through regulating the expression of E-cadherin and vascular endothelial growth factor (VEGF)-C, which are associated with the sensitivity of tumor cells to cisplatin...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29162314/clinical-characteristics-and-outcomes-of-nonurothelial-cell-carcinoma-of-the-bladder-results-from-the-national-cancer-data-base
#6
Trevor J Royce, Chun C Lin, Phillip J Gray, William U Shipley, Ahmedin Jemal, Jason A Efstathiou
OBJECTIVES: To determine the clinical characteristics, treatment patterns, and outcomes of patients with nonurothelial cell bladder cancer (NUBC) in the United States. METHODS: A total of 163,683 patients with bladder cancer from 1998 to 2014 in the National Cancer Data Base were identified. Of all, 153,262 had urothelial cell (UC) carcinoma (93.6%) and 10,421 had NUBC (6.4%) further classified as: squamous cell carcinoma (SC, 2.4%), adenocarcinoma (AC, 1.7%), neuroendocrine (NE, 1...
November 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29162067/necrotizing-fasciitis-after-high-dose-rate-brachytherapy-and-external-beam-radiation-for-prostate-cancer-a-case-report
#7
Shimpei Yamashita, Yasuo Kohjimoto, Akinori Iba, Kazuro Kikkawa, Isao Hara
BACKGROUND: In recent years, the delayed side effects associated with radiotherapy for prostate cancer have drawn the interest of urologists. Although urosymphyseal fistula is one of these delayed side effects, this serious complication is rarely described in literature and is poorly recognized. CASE PRESENTATION: We report our experience in treating a 77-year-old male patient with necrotizing fasciitis after high-dose rate brachytherapy plus external beam radiation for prostate cancer...
November 21, 2017: BMC Urology
https://www.readbyqxmd.com/read/29161267/sugar-industry-sponsorship-of-germ-free-rodent-studies-linking-sucrose-to-hyperlipidemia-and-cancer-an-historical-analysis-of-internal-documents
#8
Cristin E Kearns, Dorie Apollonio, Stanton A Glantz
In 1965, the Sugar Research Foundation (SRF) secretly funded a review in the New England Journal of Medicine that discounted evidence linking sucrose consumption to blood lipid levels and hence coronary heart disease (CHD). SRF subsequently funded animal research to evaluate sucrose's CHD risks. The objective of this study was to examine the planning, funding, and internal evaluation of an SRF-funded research project titled "Project 259: Dietary Carbohydrate and Blood Lipids in Germ-Free Rats," led by Dr. W...
November 2017: PLoS Biology
https://www.readbyqxmd.com/read/29160225/phosphatidylserine-targeted-single-walled-carbon-nanotubes-for-photothermal-ablation-of-bladder-cancer
#9
Needa A Virani, Carole Davis, Patrick McKernan, Paul Hauser, Robert E Hurst, Joel Slaton, Ricardo P Silvy, Daniel E Resasco, Roger G Harrison
Bladder cancer has a 60-70% recurrence rate most likely due to residual tumour left behind after a transurethral resection (TUR). Failure to completely resect the cancer can lead to recurrence and progression into higher grade tumours with metastatic potential. We present here a novel therapy to treat superficial tumours with the potential to decrease recurrence. The therapy is a heat-based approach in which bladder tumour specific single-walled carbon nanotubes (SWCNTs) are delivered intravesically at a very low dose (0...
November 21, 2017: Nanotechnology
https://www.readbyqxmd.com/read/29159793/curative-radiation-therapy-for-very-elderly-bladder-cancer-patients-with-localized-disease
#10
M Bonet, T Bonfill, M Nuñez, L De Verdonces, E Mur, E Gallardo, L Fernandez-Morales, A Aguilar, J Prats, M Arenas
PURPOSE: To report the outcomes of a cohort of very elderly muscle-invasive bladder cancer (MIBC) patients treated with contemporary 3D-conformal radiation therapy (3D-CRT) with or without concurrent chemotherapy, after transurethral resection of bladder tumor (TURBT). METHODS: From February 2010 to January 2014, a total of 41 patients older than 75 years, with T2-3 N0-1 high-grade MIBC, a Karnofsky index (KI) of at least 90% and/or a Barthel scale score of at least 95, were treated with TURBT followed by radiotherapy (RT) with or without chemotherapy, and were prospectively followed-up...
November 20, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29158832/clinical-translation-and-first-in-human-use-of-44-sc-sc-psma-617-for-pet-imaging-of-metastasized-castrate-resistant-prostate-cancer
#11
Elisabeth Eppard, Ana de la Fuente, Martina Benešová, Ambreen Khawar, Ralph A Bundschuh, Florian C Gärtner, Barbara Kreppel, Klaus Kopka, Markus Essler, Frank Rösch
BACKGROUND: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications...
2017: Theranostics
https://www.readbyqxmd.com/read/29158799/fluid-intake-to-bed-time-nocturia-frequency-and-the-risk-of-urothelial-carcinoma-of-the-bladder-a-case-control-study
#12
Jianfeng Cui, Qiyu Bo, Ning Zhang, Shouzhen Chen, Meng Yu, Shiyu Wang, Jie Han, Pengxiang Chen, Dongqing Zhang, Yaofeng Zhu, Benkang Shi
Objectives: To clarify the potential role of fluid intake-to-bed time and nocturia frequency on bladder cancer risk in a hospital-based case-control study with Chinese people. Materials and Methods: Four hundred and seven patients with histologically diagnosed bladder cancer and 400 matched controls were enrolled in this study. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression model. Results: After adjustment for potential confounders, the fluid intake-to-bed time was associated with a decreased risk of BCa, with an OR of 0...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158169/potential-benefit-of-lymph-node-dissection-during-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma-a-systematic-review-by-the-european-association-of-urology-guidelines-panel-on-non-muscle-invasive-bladder-cancer
#13
REVIEW
Jose Luis Dominguez-Escrig, Benoit Peyronnet, Thomas Seisen, Harman M Bruins, Cathy Yuhong Yuan, Marko Babjuk, Andreas Böhle, Maximilian Burger, Eva M Compérat, Paolo Gontero, Thomas Lam, Steven MacLennan, Hugh Mostafid, Joan Palou, Bas W G van Rhijn, Richard J Sylvester, Richard Zigeuner, Shahrokh F Shariat, Morgan Rouprêt
CONTEXT: The oncological efficacy of routine lymphadenectomy (lymph node dissection [LND]) at the time of radical nephroureterectomy (RNU) remains controversial. OBJECTIVE: To systematically review the available literature assessing the impact of LND in upper tract urothelial carcinoma (UTUC) patients. EVIDENCE ACQUISITION: Embase, Medline, and Cochrane databases were searched for all studies comparing outcomes of patients undergoing RNU without LND versus any form of LND...
November 17, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29158137/recent-developments-in-the-management-of-bladder-cancer-introduction
#14
REVIEW
Angela B Smith
An upsurge of advances in the management of bladder cancer has rapidly occurred over the past 2 years. In this issue, recent developments in the management of bladder cancer will be discussed, including the emerging role of immunotherapy, biomarkers, and advanced imaging.
November 17, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29158136/it-s-all-about-the-perspective-removing-bias-when-co-managing-patients-with-high-grade-t1-bladder-cancer-and-localized-prostate-cancer-a-competing-risks-analysis
#15
J E Ferguson, Ashish M Kamat
The risk connotation of terminology in influencing decision-making should not be underestimated. For example, "superficial" T1HG bladder cancer has the same poor cancer-specific survival as that conferred by the "highest risk" prostate cancer (Gleason 10, T3b). Co-management of concomitant prostate cancer and non-muscle invasive bladder cancer requires a careful competing risk analysis by both the physician and patient. Herein, we detail how patients and physicians should be careful not to underestimate the risk attributed to "non-muscle invasive" bladder cancer...
November 17, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29158104/impact-of-primary-tumor-location-on-survival-from-eortc-advanced-urothelial-cancer-studies
#16
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, Maria De Santis, Joaquim Bellmunt, Cora N Sternberg, Bertrand Tombal, Laurence Collette
OBJECTIVE: The prognostic relevance of primary location of urothelial carcinoma (UC) on survival has been poorly investigated. METHODS: The prospectively collected data from three EORTC advanced UC studies 30924 (M-VAC versus high dose M-VAC), 30986 (MCAVI versus GC arm, among patients unfit for CDDP) and 30987 (GC-Paclitaxel versus GC, among patients fit for CDDP) were used. Patients were grouped by primary tumor location as bladder (BCa) versus upper tract urothelial carcinoma (UTUC)...
November 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29157296/biomarkers-for-immunotherapy-in-bladder-cancer-a-moving-target
#17
REVIEW
David H Aggen, Charles G Drake
Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1 antibody pembrolizumab demonstrated improved OS relative to chemotherapy in a randomized phase III study for second line treatment of mUC; this level 1 evidence led to approval from the U...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29156782/trends-in-neoadjuvant-chemotherapy-use-and-oncological-outcomes-for-muscle-invasive-bladder-cancer-in-japan-a-multicenter-study
#18
Go Anan, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Toshikazu Tanaka, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Objective: Despite benefits of neoadjuvant chemotherapy (NAC), the adoption of guideline recommendations for NAC use in patients with muscle-invasive bladder cancer (MIBC) has been slow. We aimed to evaluate temporal trends in NAC use and oncological outcomes in a representative cohort of patients with MIBC. Methods: We included 532 patients from 4 hospitals who underwent radical cystectomy (RC) for ≥ cT2 MIBC in 1996-2017. We retrospectively evaluated temporal changes in NAC use and progression-free and overall survival...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156750/somatic-mutations-in-cdh1-and-ctnnb1-in-primary-carcinomas-at-13-anatomic-sites
#19
Evan L Busch, Jason L Hornick, Renato Umeton, Adem Albayrak, Neal I Lindeman, Laura E MacConaill, Elizabeth P Garcia, Matthew Ducar, Timothy R Rebbeck
Metastases are involved in most cancer deaths. Evidence has suggested that cancer cell detachment from primary tumors might occur largely via the mechanism of epithelial-mesenchymal transition (EMT) activated by epigenetic events, but data addressing other possible triggers of detachment, particularly genetic mutations, have been limited. Using the Profile study of cancer genomics at Dana-Farber Cancer Institute, we examined somatic mutations in the EMT genes CDH1 in 5,106 primary carcinomas and CTNNB1 in 7,578 primary carcinomas across 13 anatomic sites: urinary bladder, breast, colon/rectum, endometrium, esophagus, kidney, lung, ovary, pancreas, prostate, skin (non-melanoma), stomach, and thyroid...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29156721/a-hemoglobin-based-oxygen-carrier-sensitized-cisplatin-based-chemotherapy-in-hepatocellular-carcinoma
#20
Xiang Qi, Bing L Wong, Sze Hang Lau, Kevin Tak-Pan Ng, Sui Yi Kwok, Chris Kin-Wai Sun, Fei Chuen Tzang, Yan Shao, Chang Xian Li, Wei Geng, Chang Chun Ling, Yuen Yuen Ma, Xiao Bing Liu, Hui Liu, Jiang Liu, Wai Ho Yeung, Chung Mau Lo, Kwan Man
Background and Objective: Our previous study showed that liver graft injury not only promotes tumor recurrence, but also induces chemoresistance in recurrent HCC after liver transplantation. Recently, we found that the hemoglobin-based oxygen carrier"YQ23" significantly ameliorates hepatic IR injury and prevent tumor recurrence. Here, we intended to explore the novel therapeutic strategy using oxygen carrier "YQ23"to sensitize chemotherapy in HCC. Methods: To investigate the role of YQ23 combined with Cisplatin, the proliferation of HCC cells was examined under combined treatment by MTT and colony formation...
October 17, 2017: Oncotarget
keyword
keyword
3129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"